PMS Registry
Company Name
Novartis (Taiwan) Co., Ltd
Protocol Number
Title of Study
Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk of Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), or Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Primary Objective
To evaluate the safety profile of ruxolitinib in patients with intermediate-2 or high-risk PMF, PPV-MF, or PET-MF under routine clinical practice
Number of Sites
Period of Study
From:Jan 2017 to:Jan 2021
Number of Patients
IRB Approval Date
27 Dec 2016 (first site)
Publication Plan / Date
Jul 2022